에 대한 최신 뉴스 ABM Indus (NYSE:ABM) 주식

ABM Indus

ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVGO

SWBI

금요일 아침 (현지 시간 기준) 미국 주식 선물이 혼조세를 보이는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 ABM 인더스트리즈(NYSE:ABM)가 개장 전 매출 20억 4천만 달러에 주당 86센트의 분기 이익을 보고할 것으로 예상하고 있다. ABM의 주식은 시간 외 거래에서 3.4% 상승한 $58.00를 기록했다.

금요일 주목해야 할 주식: 브로드컴, ABM 인더스트리즈 그리고 3종목

ABM Industries Inc

ALBIOMA by Albioma

ABCOURT MINES INC B by Abcourt Mines Inc.

Abcourt Mines Inc

AMER BIO MEDICA CORP by American Bio Medica Corp.

American Bio Medica Corp

American Battery Technology Co

ABN AMRO Bank NV

ADVANCED BIOMEDICAL TECHS by Advanced BioMedical Technologies, Inc.

Advanced BioMedical Technologies Inc

UBS analyst Joshua Chan maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Neutral and raises the price target from $55 to $56.

Price Target

Analyst Ratings

UBS Maintains Neutral on ABM Indus, Raises Price Target to $56

<h3>Gainers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock moved upwards by 83.1% to $2.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $71.3 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock moved upwards by 32.81% to $0.3. The market value of their outstanding shares is at $4.8 million. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) shares rose 21.91% to $1.5. The market value of their outstanding shares is at $142.1 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares moved upwards by 17.68% to $5.79. The market value of their outstanding shares is at $75.1 million. </li>
<li>Hyzon Motors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) shares rose 13.07% to $1.9. The company's market cap stands at $14.4 million. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) stock increased by 12.58% to $0.72. The market value of their outstanding shares is at $16.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) stock declined by 16.6% to $3.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) stock decreased by 11.79% to $4.94. The market value of their outstanding shares is at $42.9 million. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock declined by 10.63% to $4.22. The market value of their outstanding shares is at $89.2 million. </li>
<li>Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) stock fell 9.49% to $77.22. The market value of their outstanding shares is at $8.0 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) shares decreased by 9.17% to $1.09. The market value of their outstanding shares is at $45.0 million. </li>
<li>ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) stock declined by 8.58% to $50.2. The market value of their outstanding shares is at $3.1 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EFSH

GWAV

HUHU

HYZN

MESA

SIDU

SYNX

VSTE

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

ABM Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) shares are trading lower after the company reported<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42549751/abm-reports-fourth-quarter-and-full-fiscal-2024-results-and-provides-fiscal-2025-outlook" rel="noreferrer noopener"> fourth-quarter FY24&nbsp;earnings</a>.
Sales grew&nbsp;4.0%&nbsp;year over year to&nbsp;$2.18 billion, beating the consensus of&nbsp;$2.079 billion. Revenue growth was driven by Technical Solutions (+35%&nbsp;Y/Y) and Aviation (+11%), with Education revenue being flat Y/Y.
Operating expenses increased&nbsp;5.4% to&nbsp;$1.91 billion, and operating profit declined&nbsp;81.9%&nbsp;to&nbsp;$19.2 million&nbsp;in the quarter.
Adjusted EBITDA fell 11%&nbsp;to&nbsp;$128.0&nbsp;million, with the margin stood at&nbsp;6.1% vs. 7.2% a year ago quarter. Adjusted EPS of&nbsp;$0.90, down 11%&nbsp;Y/Y, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;$0.87</a>.
Operating cash flow for the quarter totaled&nbsp;$30.3&nbsp;million, down from&nbsp;$139.1 million a year ago. As of October-end, ABM held cash and equivalents of&nbsp;$64.6 million.
ABM declared a cash dividend of&nbsp;$0.265&nbsp;per common share, payable on February 3, 2025, to shareholders of record on January 2, 2025. As previously announced, the dividend&nbsp;represents a&nbsp;17.8%&nbsp;increase over the <a target="_blank" href="https://www.benzinga.com//node/42350771" rel="noreferrer noopener">prior quarterly cash dividend.</a>
Scott Salmirs, President &amp; Chief Executive Officer, said, &#8220;The significant growth of our microgrid service line and the market gains we made in Aviation were critical to overcoming challenges in other parts of the business. These results support our diversification strategy.&#8221;
&#8221;While it is still early and the macro environment is unclear following the recent election, recent data points suggest our key commercial real estate markets are nearing an inflection to growth. Additionally, other parts of our business are continuing to experience generally healthy market conditions.&#8221;
2025 Outlook: ABM expects FY25 adjusted EPS&nbsp;of&nbsp;$3.60 &#8211; $3.80&nbsp;vs.&nbsp;consensus of $3.66&nbsp;and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">adjusted EBITDA margin of&nbsp;6.3%-&nbsp;6.5%</a>.
The company expects revenue, margin, and earnings growth in 2025, citing the positive backdrop.
Price Action: ABM shares are down 8.58% at $50.20&nbsp; at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42554393" target="_blank" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a></li>
</ul>

Equities

Mid Cap

ABM Industries Stumbles Despite Q4 Earnings Beat - What's Going On?

Guidance

ABM Sees FY25 Adjusted EPS Outlook Of $3.60-$3.80 Vs. $3.66 Est., Adjusted EBITDA Margin Of 6.3% to 6.5%

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.87 by 3.45 percent. The company reported quarterly sales of $2.177 billion which beat the analyst consensus estimate of $2.079 billion by 4.71 percent. This is a 4.03 percent increase over sales of $2.093 billion the same period last year.

Earnings Beats

ABM Indus Q4 2024 Adj. EPS $0.90 Beats $0.87 Estimate, Sales $2.177B Beat $2.079B Estimate

<h3>Companies Reporting Before The Bell</h3>
• SPDR Bloomberg Convertible Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWB#NYSE">CWB</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $304.67 million. 
• Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) is likely to report earnings for its first quarter. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $43.78 million. 
• Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) is estimated to report quarterly earnings at $1.83 per share on revenue of $6.61 billion. 
• General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) is projected to report quarterly earnings at $1.22 per share on revenue of $5.13 billion. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $2.07 billion. 
• Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $439.27 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is projected to report quarterly earnings at $1.05 per share on revenue of $1.11 billion. 
<h3>Companies Reporting After The Bell</h3>
• cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $4.81 million. 
• Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is projected to report quarterly earnings at $4.26 per share on revenue of $10.08 billion. 
• Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $150.00 million. 
• Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $724.35 million. 
• Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $812.02 million. 
• Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is likely to report quarterly earnings at $1.76 per share on revenue of $8.55 billion. 
• MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $959.70 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIRK

Spdr Barclays Capital Convertible Securities Etf

EPAC

MLKN

TKLF

YCBD

Earnings Scheduled For December 18, 2024

ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/ABM/earnings">opening bell on Wednesday, Dec. 18.</a>
Analysts expect the New York-based company to report quarterly earnings at 87 cents per share, down from $1.01 per share in the year-ago period. ABM Industries projects to report revenue of $2.08 billion for the recent quarter, compared to $2.09 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 5, ABM raised its quarterly dividend from 22.5 cents to 26.5 cents per share.
ABM shares gained 1.1% to close at $56.76 on Monday.
Benzinga readers can access the latest analyst ratings on the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ABM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>UBS analyst Joshua Chan maintained a Neutral rating and raised the price target from $51 to $55 on Sept. 9. This analyst has an accuracy rate of 71%.</li>
<li>Truist Securities analyst Jasper Bibb maintained a Hold rating and increased the price target from $49 to $55 on Sept. 9. This analyst has an accuracy rate of 77%.</li>
<li>Baird analyst Andrew Wittmann maintained a Neutral rating and increased the price target from $49 to $56 on Sept. 9. This analyst has an accuracy rate of 81%.</li>
</ul>
Considering buying ABM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17023225/image-136-1024x456.png" alt="" class="wp-image-695245" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17023225/image-136-1024x456.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17023225/image-136-300x134.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17023225/image-136-768x342.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17023225/image-136.png 1447w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42509800/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a></li>
</ul>

ABM Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dividends

ABM Increases Quarterly Dividend From $0.225 To $0.265

<a href="https://www.globenewswire.com/Tracker?data=dDt0M3F1yrxUZhKJuN9jE3I0EZP6iMCtbu_r8oP0QvcTAM4t8ORGDnIKlLeTq2unqUOoUgtXb-9nAnI8D1msOg==">ABM (NYSE:</a><a href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>), a leading provider of integrated facility services, infrastructure solutions, and parking management today announced a strategic partnership with <a href="https://www.globenewswire.com/Tracker?data=IdQ6h-8JPvpeYyPhMgh6axiAEL-6JlfN4eYNthQaCSMQN-X2tAIE34R3GTfDP1dpXVN7ZWge1gcU-6YHIEZaTmkeuu1waU9nxqjiL2rLhsQ=">Mainspring Energy, Inc</a>., in which ABM will deploy Mainspring's cutting-edge Linear Generator technology to enhance electric vehicle ("EV") charging solutions for fleet, commercial and industrial clients that require turnkey offerings and on-site power generation projects.
The availability and reliability of the power needed to support commercial fleets is often a main obstacle for commercial fleet operators seeking to deploy electrification strategies. Mainspring's state-of-the-art Linear Generators provide efficient, on-site power by converting linear motion into electricity. The differentiated fuel-flexible generators can also directly run on highly sustainable renewable and zero-carbon fuels such as biogas, hydrogen, and ammonia, as well as traditional fuels like natural gas and propane, providing clients with important flexibility.
The technology's ability to be quickly deployed at scale is particularly appealing to large fleet operators seeking to quickly and cost-effectively deploy resilient EV charging infrastructure while reducing emissions and working toward net-zero goals.

ABM Announces A Strategic Partnership With Mainspring Energy, In Which ABM Will Deploy Mainspring's Linear Generator Technology To Enhance EV Charging Solutions For Fleet, Commercial And Industrial Clients That Require Turnkey Offerings And On-site Power Generation Projects

<a href="https://www.globenewswire.com/Tracker?data=u__EcdHyxyoNqn01p2yG1vMlvN47sF2FkFGe-sdX9GqR7I8HbDcDvEmZIPlZ_Yn7tZ_u1HkDpxUgsHgDNw1rAA==">ABM (NYSE:</a><a href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>), a leading provider of integrated facility services, infrastructure solutions, and parking management, today announced a distributorship agreement with <a href="https://www.globenewswire.com/Tracker?data=6xDlfYiK6RHtxZ1B-aj2ncXx1sxHNVHZ23D8Jn-FH-DacqXwzc2NmQpLGqLUrmu579-M9-ewGQne0QCgid1glNP6MsNZVVW4WVYDCHLE154=">Samsung C&amp;T</a> Charging Solutions, making ABM an authorized distributor and servicer of EVSIS-branded DC Fast Chargers. Samsung C&amp;T Charging Solutions is an equity partner of the Korean DC Fast Chargers manufacturer EVSIS, which is entering the United States market. &nbsp;
The EVSIS chargers are versatile and high-quality, with best-in-class technology that integrates seamlessly with the cloud-based <a href="https://www.globenewswire.com/Tracker?data=3c82g6zuJHtSlAHprFkNAjBjCYt4m5ugaDVEOVcjLBVGGtXdtXbKN6PSQ4TiIUyBdFMVw9x56CoPQqtRjRUAKqPsYPA9-GcgvqBAg1U9nPthwR9LjjsCsSJBg959koScU7oe-2KGY5oqZMnC1Uz5TYgdBXupjsqJNA735KYBiZHgs8yPctcL0MeitK3PEKsTO_vCxScGVvr1Q1PFuoaF0iHFUJwUjGX3u_EkgihogBxHnqjEywISQD2bnXgqzSvz0G3rT_IQdZUhMe-GA8Ce17UE5ttef9FVGvhiodgkpUBff-2OOtbhOEl9ceGNmMo58EaHEBBQRmerk_yLD9fSjFZ4pxTvB5AKdTBcbqz7MZZnMHMRNIQ43EmEh1eYKI0Isdp8A7k_IJiSU_BJGBCiI_t_0TfM6S1_X2aNHctrDOgro76lkXPT31tsJY1C4kjqG2R8UT3NtxMlke190kGPGFCP5DcqAA6RndYJmFzjAoeAN2Cb11pcq_PBpDJpKjiEJzwayugvIqKALSnJmxxGt3VlHs1HPC1kDc-n022mlpPz22CAKJypZIMvWFI_1Mg6sgrmgDrlzLjwAmk7AxQO1h5QZtK3pFGCJ4Hu_3AMtDyQDttkFPb7m3dy1l_Mr6mFxCVjq8ipJQcT7FGm4N_v84nC7WOreAwkazTulVdnMAgZLoPUqHwqp0ZyuMTfJG8DPGkIP2KVT6AI2OnUXnq6K0q5n-0NKitWaXP0_GmHnBREYeuE19LbJTfVKELSl1xz_4LXljkXpixEzPGnFAMjAJK4KmW2HMKpC5qZba28AO6004-TyTVx8QQMsXfEDPWIUXlzjfmsdmmuKb-wwB4_jZPUAMSQhECTNd6JAhZpHWW8ZRhQ7uyn_rft56grwjI-2jCXDWfItZ-DFdsu6dh6risAwVOVDF89u2GcC7jcIbxKZNlpVdmEmnq5Kca4hbSMwQGdBPM5jPbpIOb-28flmk2PVYoEPl2mz4Z4qnnM6AVppBeA8Xgx8LuzEGpOmHGBX1zeiy5lHdkQjGIIVAlbAW-AuFOmQjgEtwgRFbgnOGcgVmQdlcz1sYT-YjQnuP_qAQ2Nshrdbw9B3zyzDxenKk2vbnO-9Qqyx0VkdoW6ddwWkGPmOPlgmsQuzhs5wJ4a">ABM EV OS</a> platform – enabling for scalable expansion, intelligent monitoring, remote operation management, comprehensive reporting, and automatic infrastructure diagnostics. Through this partnership, all EVSIS chargers will be offered and serviced alongside ABM's current charger portfolio.

SSNLF

ABM Expands Charger Portfolio With Samsung C&T Charging Solutions Partnership

GE HealthCare Technologies&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification.
With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient&#39;s brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer&#39;s disease.
<h2>Likely Trend of GEHC Stock Following the News</h2>
Following the announcement, shares of the company moved nearly 1.7% north to $88.53 at yesterday&#39;s close.
GE HealthCare is one of the leading providers of medical technology, pharmaceutical diagnostics, and digital solutions with a focus on precision care. In March, GE Healthcare acquired MIM Software, which added AI-based solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics and research organizations worldwide. Owing to the strong potential for the diagnostic imaging market, we expect the market sentiment to remain positive around this news.
Meanwhile, GEHC currently has a market capitalization of $39.63 billion. It has an earnings yield of 4.91% is much higher than the industry&#39;s yield of negative (7.12)%. In the last reported quarter, GEHC delivered an earnings surprise of 2.04%.
<h2>More on the GEHC&#39;s Centiloid Scaling Tool</h2>
A significant number of people in the United States develop dementia, with Alzheimer&#39;s disease accounting for 60-80% of dementia cases. The condition affects memory, thinking and behavior, and symptoms typically start with mild cognitive impairment and eventually grow severe enough to interfere with daily tasks. A characteristic feature of this condition is the build-up of beta-amyloid protein in the brain, which is connected to tissue loss and cell death.
In order to assist physicians in identifying potential patients for amyloid-targeting therapies, PET imaging makes it possible to visualize and quantify amyloid protein. A global consortium of physicians and scientists created the Centiloid scale with the goal of harmonizing quantitative amyloid imaging analysis throughout radiotracers and organizations.
GE HealthCare&#39;s MIM Software now offers MIMneuro with Centiloid scaling, leveraging an automated workflow to help guide users through generating and understanding the quantitative result. The software takes the PET amyloid images, provides clinicians instructions to automatically generate quantitative results, and presents the data in a standardized report for clinicians to review alongside the images. As a result, clinicians can more easily access the quantitative data they need to evaluate patients.
MIMneuro with Centiloid scaling is the latest addition to GE HealthCare&#39;s comprehensive suite of products and solutions, which span the Alzheimer&#39;s disease care pathway from diagnosis through treatment monitoring.
<h2>Favorable Industry Prospects for GEHC</h2>
Per a report by Future Market Insight, the global brain imaging and neuroimaging market was estimated to be $13.7 billion in 2023 and is anticipated to surpass $22.4 billion by 2033 at a CAGR of 5.1%. The brain imaging and neuroimaging market is primarily driven by the rising incidence and prevalence of neurological disorders, increased awareness of neurodegenerative diseases, an increase in traumatic brain injuries, and increased applications of brain imaging and neuroimaging in clinical trials.
Given the market potential, the latest FDA clearance of MIM Software&#39;s Centiloid Scaling Tool is likely to provide a boost to GEHC&#39;s business.
<h2>GEHC&#39;s Notable Developments</h2>
In August, GEHC announced the receipt of the CE mark for its Vscan Air SL wireless handheld ultrasound system with Caption AI. The company also received the CE mark for the use of ECG-less cardiac computed tomography scanning on its Revolution Apex platform.
The company also collaborated with the University of California San Diego School of Medicine. The tie-up aims to investigate advanced magnetic resonance imaging protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians.
<h2>GEHC&#39;s Price Performance</h2>
In the past six months, GEHC shares have lost 2.6% compared with the industry&#39;s decline of 12.4%. The S&amp;P 500 has gained 7.6% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/51/78442.jpg?v=1728486434" />
Image Source: Zacks Investment Research
<h2>GE HealthCare&#39;s Zacks Rank &amp; Stocks to Consider</h2>
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2338704/gehc-stock-rises-as-fda-clears-mim-software-s-centiloid-tool?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2338704">To read this article on Zacks.com click here.</a>

Biotech

Large Cap

General

GEHC

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

Solventum Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/solv#NYSE">SOLV</a>) recently announced the launch of the V.A.C. Peel and Place Dressing, an integrated dressing and drape that can be applied quickly&nbsp;and worn by patients for up to seven days.
Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be changed at least three times a week.
The latest launch by SOLV is likely to solve the persisting issues of traditional dressings for negative pressure wound therapy, making it more accessible and less painful. The V.A.C. Peel and Place Dressing is an essential innovation in wound care that has the potential to improve outcomes, save both time and money and enhance the overall patient and clinician experience.
Due to the factors mentioned above, the product is likely to witness substantial demand in the field of negative pressure wound therapy and contribute to the top-line growth of the company, thus driving the share price of SOLV higher.
<h2>More on the SOLV&#39;s V.A.C Peel and Place Dressing</h2>
The latest development in V.A.C.&nbsp;Therapy is the new V.A.C.&nbsp;Peel and Place Dressing. Due to its integrated dressing and drape design, dressing application and changes are easier to perform, requiring less time and training. Moreover, it has an integrated non-adherent, perforated layer that reduces tissue ingrowth and lessens discomfort when removing the dressing.
The V.A.C. Peel and Place Dressing is suggested for use on wounds up to 6 cm deep, covering chronic, acute, traumatic, subacute, and dehisced wounds. Additionally, it can be used on partial thickness burns, pressure ulcers (such as those caused by diabetes), venous insufficiency, flaps, and grafts.
Research has demonstrated that the V.A.C. Peel and Place Dressing can substantially reduce&nbsp;therapy application time. It can also lower hospital bedside expenditures significantly&nbsp;because of fewer dressing changes and lower&nbsp;home nursing visits per week.
V.A.C.&nbsp;Therapy has been linked to noticeably faster wound healing. Over nearly three decades, it has been used globally to treat more than 10 million wounds. However, a rise in wound numbers is increasing due to aging populations and the incidence of chronic illnesses such as obesity and diabetes. The V.A.C. Peel and Place Dressing enables V.A.C. Therapy to be used on a wider range of patients across the continuum of care in both acute and post-acute settings.
The product is available now in the United States and Canada. Additional global regulatory submissions and approvals are pending.
<h2>Favorable Industry Prospects for SOLV</h2>
Per a report by Grand View Research, the global negative pressure wound therapy market size was estimated to be $2.5 billion in 2023 and is expected to witness a CAGR of 6.6% from 2024 to 2030.
Given the market potential, SOLV&#39;s V.A.C Peel and Place Dressing is likely to provide a boost to SOLV&#39;s business.
<h2>SOLV&#39;s&nbsp;Price Performance</h2>
In the past six months, SOLV shares have lost 1.1% compared with the industry&#39;s decline of 1.3%. The S&amp;P 500 has gained 6.4% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9f/77363.jpg?v=2024522534" />
Image Source: Zacks Investment Research
<h2>SOLV&#39;s Zacks Rank and Stocks to Consider</h2>
Currently, SOLV has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries presently carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 56.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;48.1% rise.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 13.9% so far this year compared with the&nbsp;industry&#39;s&nbsp;17.9% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 27.4% so far this year compared with the&nbsp;industry&#39;s&nbsp;17% growth.
<a href="https://www.zacks.com/stock/news/2334834/solventum-shares-may-gain-on-the-launch-of-its-new-v-a-c-therapy?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334834">To read this article on Zacks.com click here.</a>

Health Care

Events

SOLV

Solventum Shares May Gain on the Launch of Its New V.A.C Therapy

UBS analyst Joshua Chan maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Neutral and raises the price target from $51 to $55.

UBS Maintains Neutral on ABM Indus, Raises Price Target to $55

Truist Securities analyst Jasper Bibb maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Hold and raises the price target from $49 to $55.

Truist Securities Maintains Hold on ABM Indus, Raises Price Target to $55

Baird analyst Andrew Wittmann maintains ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) with a Neutral and raises the price target from $49 to $56.

Baird Maintains Neutral on ABM Indus, Raises Price Target to $56

WIIM

ABM Industries shares are trading lower. The stock gained after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates but has since reversed.

ABM Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) shares are trading higher after the company reported&nbsp;third-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40746750/abm-reports-third-quarter-fiscal-2024-results-and-raises-outlook-for-fiscal-year-2024-adjusted-eps" rel="noreferrer noopener">earnings and raised&nbsp;guidance</a>.
Sales grew 3.3% Y/Y to $2.09 billion, beating the consensus of $2.037 billion. Revenue growth was driven by Technical Solutions (+25% Y/Y) and Aviation (+13%), with Education increasing by 4% Y/Y.
Operating expenses increased&nbsp;3.7%&nbsp;Y/Y to&nbsp;$1.83 billion, and operating profit declined&nbsp;73.1% Y/Y to&nbsp;$37.4 million in the quarter.
Adjusted EBITDA rose 2% Y/Y to $128.1 million, with the margin remaining flat Y/Y at 6.4%. Adjusted EPS of $0.94, up 19% Y/Y, beating <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">the consensus of $0.86</a>.
Operating cash flow for the quarter totaled&nbsp;$79.5 million, down from&nbsp;$149.1 million&nbsp;a year ago. As of July-end, ABM held cash and equivalents of&nbsp;$86.3 million.
Dividend:&nbsp;ABM declared a cash dividend of&nbsp;$0.225&nbsp;per common share, payable on November 4, 2024, to shareholders of record on October 3, 2024.
Scott Salmirs, President &amp; Chief Executive Officer, said, &#8220;Our investments in the energy resiliency markets, particularly in microgrids, which grew significantly, as well as those investments in technology, including tools that improve labor efficiency and our go-to-market approach, helped us deliver another quarter of solid organic growth on an enterprise level and resilient margins.&#8221;&nbsp;
&#8220;This performance was supported by our focus on market segmentation, especially our purposeful weighting towards higher performing Class A properties, which enabled us to once again perform well in our Business &amp; Industry segment, despite a still choppy commercial real estate environment.&#8221;
2024&nbsp;Outlook: ABM raised the adjusted EPS outlook to&nbsp;$3.48 &#8211; $3.55 (from $3.40 &#8211; $3.50)<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> versus the&nbsp;$3.47&nbsp;consensus</a>.
Price Action: ABM shares are up 6.95%&nbsp;at&nbsp;$60.00 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40746080/us-stocks-set-for-steep-fall-amid-heightened-anxiety-ahead-jobs-data-vix-surges-strategist-flags-2-" target="_blank" rel="noreferrer noopener">US Stocks Set For Steep Fall Amid Heightened Anxiety Ahead Jobs Data, VIX Surges: Strategist Flags 2 Reasons Why He Expects More Volatility Ahead</a></li>
</ul>

ABM Industries Delivers Solid Q3 Results On Investment In Energy Market, Boosts Guidance

ABM Industries shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

ABM Raises FY24 Adjusted EPS Outlook To $3.48-$3.55 (From $3.40-$3.50 ) Vs. $3.47 Est.

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.86 by 9.3 percent. The company reported quarterly sales of $2.094 billion which beat the analyst consensus estimate of $2.037 billion by 2.81 percent. This is a 3.25 percent increase over sales of $2.028 billion the same period last year.

ABM Indus Q3 2024 Adj. EPS $0.94 Beats $0.86 Estimate, Sales $2.094B Beat $2.037B Estimate

ABM Industries Incorporated (ABM) Q4 2024 Earnings Call Transcript

ABM Industries: A Dividend Champion Just Went On Sale

Abm Industries Incorporated ( ($ABM) ) has released its Q4 earnings. Here is a breakdown of the information Abm Industries Incorporated presented t...

ABM Industries Reports Strong Growth and Future Prospects

Truist Financial analyst Jasper Bibb assigned a Hold rating to the stock yesterday. The company's shares opened today at $50.65. Bibb covers the In...

Comments

ABM Indus

뉴스

에 대한 최신 뉴스 ABM Indus (NYSE:ABM) 주식

금요일, 9월 06, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌